ScholarIQanswers from OpenAlex & ORCID
Nicholas J. Vogelzang
ResearcherPublications, citations & collaboration network
Nicholas J. Vogelzang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nicholas J. Vogelzang have?
ScholarIQindexed works
Nicholas J. Vogelzang has 1,125 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nicholas J. Vogelzang have?
ScholarIQcitation count
Nicholas J. Vogelzang has 69,898 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nicholas J. Vogelzang?
ScholarIQh-index
Nicholas J. Vogelzang has an h-index of 116 in OpenAlex.
What is the i10-index of Nicholas J. Vogelzang?
ScholarIQi10-index
Nicholas J. Vogelzang has an i10-index of 512 in OpenAlex.
What is the ORCID of Nicholas J. Vogelzang?
ScholarIQorcid
The ORCID for Nicholas J. Vogelzang is on the source record.
What is the OpenAlex record for Nicholas J. Vogelzang?
ScholarIQopenalex
The OpenAlex for Nicholas J. Vogelzang is on the source record.
What are the most-cited papers on Nicholas J. Vogelzang?
ScholarIQmost cited works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain, Catherine M. Tangen, Donna L. Berry, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen M. Prescott, S.K. Sundaram, Eric J. Small, Nancy A. Dawson, Bryan Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Benjamin Ely, Carol M. Moinpour, Nicholas J. Vogelzang, Ian M. Thompson
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher